Bioassay Methods Group
- bbd Expand or Collapse
- About BBD Expand or Collapse
- Core Capabilities Expand or Collapse
- Cell Measurements Expand or Collapse
- Genomic Measurements Expand or Collapse
- Cancer Biomarker Measurements Expand or Collapse
- Genome Editing Measurements
- Microbial Genomic Measurements
- Genome in a Bottle Consortium
- ERCC Control Materials Expand or Collapse
- Advanced Imaging Expand or Collapse
- Biomaterials Expand or Collapse
- Microbial Metrology
- Primary Focus Areas Expand or Collapse
- Measurement Assurance Strategies Expand or Collapse
- Standards and Reference Materials Expand or Collapse
- Collaborations and Partnering
The Bioassay Methods Group develops standards and methods for improving confidence in fundamental measurements in biology through new and improved techniques, methodologies, and standards based on optical and genomic methods. We are focused on improving the quantitative measurements of biological markers of gene expression in eukaryotic cells and biological fluids. We are providing tools that can be used for bioanalytical measurements pertinent to instrument calibration and analytical validation. We work with the stakeholders in the research and clinical analysis communities to determine their needs and opportunities where we can strategically focus our efforts. We identify the existing and future standards needs ranging from device calibration and instrument performance to the development of biological reference materials and procedures. The group has active projects in the development of genomic standards to support cancer diagnostics and therapeutics, in reference materials for quantitative flow cytometry, in the development of genomic markers for cell line authentication, and in measurements for assessing the results of genome editing.
Precision Medicine for Cancer Diagnostics—The conventional approach to medicine is rapidly changing to a data-driven strategy in which therapies are individually targeted to a patient based on genome, physiology, environment, or lifestyle...
Measurement of Low Frequency Mutations in Circulating Tumor DNA (ctDNA) through Interlaboratory Testing—A very exciting development in the diagnosis and therapeutic monitoring of cancer is the discovery that blood and urine contain nucleic acids derived from cancer cells that can be used to as biomarkers...
Quantitative Flow Cytometry—We work in collaboration with other government agencies, private industry, academia, professional societies, and other national metrology institutes to ensure that flow cytometry measurements are …
Thermodynamics of Enzyme-catalyzed Reactions—To develop the thermodynamic data and methodology required for effective bioprocess engineering...
Quantification of Cells with Specific Phenotypic Characteristics—Flow cytometers are versatile instruments that have been successfully used to enumerate cell subsets in infectious diseases (e.g., HIV) and to diagnose malignancies through changes in the …
News & Publications
- Assignment of the Number of Equivalent Reference Fluorophores to Dyed Microspheres
- Automated Spectral Smoothing with Spatially Adaptive Penalized Least-Squares
- Certified DNA Reference Materials to Compare HER2Gene Amplification Measurements Using Next-Generation Sequencing Method
- Enzyme Catalyzed Reactions in Biocalorimetry: Foundations and Contemporary Approaches, Biocalorimetry: Foundations and Contemporary Approaches, CRC Press
- NIST and Frederick National Laboratory for Cancer Research Help Ensure Accurate Clinical Measurements of HER2 Breast Cancer Gene
- Standards for Cell Line Authentication and Beyond
- Relative intensity correction of Raman spectrometers: NIST SRMs 2241 through 2243 for 785 nm, 532 nm, and 488 nm/514.5 nm excitation
- Use of Standard Reference Material 2242 (Relative Intensity Correction Standard for Raman Spectroscopy) for Microarray Scanner Qualification